At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 208 target
Drug / intervention
Vortioxetine 10 mg +1 moredrug
Likely dose
Vortioxetine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Controlled Clinical Trial of Votioxetine in the Treatment of Depression After Radiotherapy for Head and Neck Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted Mar 26, 2021·Updated Mar 26, 2021
In Brief
A Phase 3 clinical trial evaluating Vortioxetine 10 mg and Placebo for Radiation Injuries. Targeting 208 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effects of vortioxetine, once daily (QD), on mood disorders and cognitive dysfunction in patients with head and neck cancers undergoing radiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Injuries
CountriesChina
Timeline
Phase 3UnknownOverdue
202120222023202420252026
Enrollment StartOct 2020
First PostedMar 2021
Primary CompletionOct 2023
Study CompletionApr 2024
TodayJul 2026
First PostedMar 26, 2021
Enrollment StartOct 10, 2020
Primary CompletionOct 10, 2023
Study CompletionApr 1, 2024
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 5.3 years ago
Interventions
Vortioxetine 10 mgdrug
Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.
Placeboother
Placebo will be used with a dosage of one tablet once a day for 2 months.